Sanofi

$49.79
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.28 (+0.57%) Today
$0.00 (0.00%) As of 8:00 PM EST after-hours

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, options, ETFs, and crypto commission-free!

About SNY

Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. Read More The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities. This segment also includes all associates whose activities are related to pharmaceuticals. The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for its Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines. The company was founded in 1973 and is headquartered in Paris, France.

Employees
104,226
Headquarters
Paris, Ile-de-France
Founded
1973
Market Cap
123.32B
Price-Earnings Ratio
30.02
Dividend Yield
2.32
Average Volume
3.33M
High Today
$49.89
Low Today
$49.48
Open Price
$49.48
Volume
3.14M
52 Week High
$49.89
52 Week Low
$40.00

Collections

SNY News

Washington PostDec 10

Flagging French Drug Giant Tries a Familiar Remedy

All of the moves make some sense and are in line with what other large drugmakers, including his prior employer, have tried in recent years. The key to success
3
BenzingaDec 10

Regeneron Shares Swing On Sanofi's Hint At Sale Of Ownership Stake, Amendments To Drug Collaborations

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares were rebounding Tuesday as investors digested French pharma giant and collaboration partner Sanofi SA's (NAS
153
MarketWatchDec 10

Regeneron shares fall on Sanofi's new direction

Sanofi fr:sny and Regeneron Pharmaceuticals REGN, -1.78% announced plans to restructure two drug-development collaborations after Sanofi announced a new directi
58

SNY Earnings

$0.63
$1.12
$1.61
$2.10
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
Actual
Available Feb 6, Pre-Market

You May Also Like

More SNY News

MarketWatchDec 10

Sanofi says trial of sutimlimab met main goals

Sanofi SA SNY, -1.59% said a Phase 3 trial of sutimlimab in people with primary cold agglutinin disease met its primary and secondary endpoints. The primary ef
21
MarketWatchDec 10

Regeneron shares fall as Sanofi signals stake sale

Shares of Regeneron Pharmaceuticals Inc. REGN, +0.54% slipped more than 3% in premarket trading Tuesday after French partner Sanofi SA (SAN.FR) indicated it wou
41
BloombergDec 10

Sanofi’s CEO Quits Diabetes as Cancer Breakthroughs Beckon

(Bloomberg) -- Sanofi’s new chief executive, just three months into the job, is taking a scalpel to traditional areas of research to rejuvenate the sluggish Fre
2
ReutersDec 10

Sanofi shares rally on new margin goals, narrower drug focus

PARIS (Reuters) - Shares in Sanofi (SASY.PA) rose on Tuesday after the French drugmaker said it would focus on vaccines and treatments like its promising eczema
4
ReutersDec 10

CORRECTED-Sanofi shares rally after firm narrows focus on key drugs

(Corrects day in lead paragraph to Tuesday) PARIS, Dec 10 (Reuters) - Shares in Sanofi rose on Tuesday after the French drugmaker said it was discontinuing res
4
MarketWatchDec 9

Insulin-giant Sanofi to exit diabetes research

The maker of the world's biggest-selling insulin has given up on finding new diabetes drugs. Sanofi SA, which makes Lantus, said Monday it would stop investing
8
ReutersDec 9

Sanofi ends research in diabetes, narrows units to spur profit

PARIS (Reuters) - Sanofi SA said on Monday it would end its research efforts in diabetes and cardiovascular diseases as part of a revamp that will narrow the nu
7
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.
Search
LearnBlogCareersHelpLog InSign Up